Pacira BioSciences (NASDAQ:PCRX) Stock Rating Lowered by Wall Street Zen

Pacira BioSciences (NASDAQ:PCRX) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other analysts also recently commented on PCRX. Truist Financial reduced their price objective on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Finally, Barclays started coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.75.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $21.91 on Friday. The company’s fifty day moving average is $22.65 and its two-hundred day moving average is $23.84. Pacira BioSciences has a 52-week low of $18.80 and a 52-week high of $27.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. The firm has a market capitalization of $887.14 million, a price-to-earnings ratio of 146.07 and a beta of 0.21.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The company had revenue of $196.87 million for the quarter, compared to analyst estimates of $201.93 million. During the same period in the prior year, the company posted $0.91 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Equities research analysts forecast that Pacira BioSciences will post 2.41 EPS for the current year.

Insiders Place Their Bets

In other Pacira BioSciences news, CFO Shawn Cross sold 15,896 shares of Pacira BioSciences stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88. Following the completion of the transaction, the chief financial officer directly owned 56,250 shares of the company’s stock, valued at approximately $1,407,937.50. This trade represents a 22.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lauren Riker sold 4,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the sale, the senior vice president directly owned 52,313 shares in the company, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,416 shares of company stock valued at $744,315. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. boosted its holdings in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after acquiring an additional 721 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Pacira BioSciences by 5,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after purchasing an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Pacira BioSciences in the 4th quarter valued at $48,000. Eurizon Capital SGR S.p.A. acquired a new position in Pacira BioSciences in the fourth quarter worth $51,000. Finally, Global Retirement Partners LLC boosted its stake in Pacira BioSciences by 479.4% in the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after purchasing an additional 1,678 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Trending Headlines about Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.